Navigation Links
YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
Date:11/11/2009

MISSISSAUGA, ON, Nov. 11 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for the first quarter of fiscal 2010, ended September 30, 2009.

"During our first fiscal quarter, we continued to advance our lead drug nimotuzumab, which is being developed globally through a network of cooperative relationships. We enrolled the first patients in our YM-sponsored multinational, randomized, Phase II double-blind trial evaluating nimotuzumab in patients with brain metastases from non-small-cell lung cancer (NSCLC) and continued to enroll patients in our randomized Phase II trial of nimotuzumab in NSCLC patients ineligible for radical chemotherapy. The US Treasury Department cleared YM's subsidiary, YM BioSciences USA Inc., of any limitations in clinical trials in the US for nimotuzumab in cancer indications and we are proposing to add US centers to these trials and potentially other trials being conducted by our licensees if and when cleared by the FDA," said David Allan, Chairman and CEO of YM BioSciences.

Subsequent to the end of the quarter we announced our proposal to merge Cytopia Ltd., an Australian clinical-stage drug development company, into YM. We believe Cytopia's lead products hold significant unrecognized potential and will benefit from YM's clinical and regulatory expertise and our access to the US capital markets," added Mr. Allan. Cytopia's lead products are CYT997, a novel, orally-available vascular disrupting agent (VDA) currently in Phase II trials, and CYT387, a novel, orally-active JAK1/2 inhibitor that recently received clearance from the FDA to commence a Phase I trial in myeloproliferative disorders which is planned to be initiated at Mayo Clinic in this current quarter. The meeting of Cytopi
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 Pursuit Solutions ... optimization technology and services for Life Sciences sales ... Pharma’s Use of New Commercial Sales Models” by ... Analytics. , The article examines some innovative models ... are being tested in the pharmaceutical market. Robinson ...
(Date:8/21/2014)... 21, 2014 On Wednesday of last week ... use Redox Signaling molecules, became available for purchase in Australia ... "The way that RENU 28 works is, if you think ... of the rate of cellular renewal within your body. If ... of that rate of cellular renewal. What RENU 28 does ...
(Date:8/20/2014)... measuring vibrational motion of a single molecule with a ... a single molecule differs from the behaviour of larger ... the University of California, Irvine, where post-doctoral researcher Eero ... visiting fellow under professor Vartkess A. Apkarian, whose team ... by Professor Eric O. Potma. The results of the ...
(Date:8/20/2014)... Aug. 20, 2014  PAREXEL International Corporation (NASDAQ: ... presenting at the Baird Healthcare Conference in New York.  ... Financial Officer, will be making a presentation on PAREXEL ... Wednesday, Sept. 3, 2014. A live webcast ... section of PAREXEL,s website at www.PAREXEL.com in ...
Breaking Biology Technology:Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2RENU 28 Skin Care Now Available in Australia and New Zealand 2Seeing a molecule breathe 2PAREXEL International To Present At Baird Healthcare Conference 2
... BSP Biological Signal Processing Ltd. ... the non-invasive, accurate diagnosis of Coronary Artery Disease (CAD), ... research study evaluating the performance of the company,s HyperQ ... and its results was accepted for publication in the ...
... , This release is available in German ... with the Max Planck Society and the German Cancer Research ... super-resolution STED (Stimulated Emission Depletion) microscopy. This gives Leica Microsystems ... into a commercial product and put it on the market. ...
... Md., Nov. 11, 2011 Spherix Incorporated (NASDAQ: ... therapy in diabetes, metabolic syndrome and atherosclerosis, and providers ... biotechnology and pharmaceutical companies -- today reported financial results ... 2011. Recent and Upcoming Highlights ...
Cached Biology Technology:Positive Clinical Study Results for BSP's HyperQ Technology 2Positive Clinical Study Results for BSP's HyperQ Technology 3Gated STED -- developing the next generation of super-resolution microscopes 2Spherix Announces Third Quarter Financial Results 2Spherix Announces Third Quarter Financial Results 3Spherix Announces Third Quarter Financial Results 4Spherix Announces Third Quarter Financial Results 5Spherix Announces Third Quarter Financial Results 6Spherix Announces Third Quarter Financial Results 7
(Date:8/20/2014)... Arizona State University, the Wellcome Trust Sanger Institute and ... isolated Mycobacterium pinnipedii from skeletons found in ... pathogen is a relative of the TB bacterium that ... today. These researchers assume that seals carried the pathogens ... sea lions was unexpected" comments Sebastien Gagneux, from the ...
(Date:8/20/2014)... Cancer Research UK scientists have discovered that acral melanomas ... Bob Marley,s death are genetically distinct from other more ... is external) published in the journal Pigment Cell & ... palms of the hands, soles of the feet, nail-beds and ... types of melanoma, it,s not caused by UV damage from ...
(Date:8/20/2014)... and plastic bags could one day be made out ... scientists are now reporting. The novel process they developed ... with its agricultural and plastic waste problems, appear in ... Ilker S. Bayer and colleagues at the Italian Institute ... growing. In 2012, its production reached 288 million tons ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2
... forks, researchers at Pacific Northwest National Laboratory have ... promises to meet or exceed current and emerging ... technique, called Quartz Laser Photo-Acoustic Sensing, or "QPAS," ... , PNNL, a Department of Energy national ...
... Rochester scientists, while investigating the two most frequent types ... to treatment that would take advantage of the mutations ... reported online this week in the journal Nature Structural ... human cells, co-authors Mingxuan Xia, Ph.D., and Hartmut Land, ...
... mutation that causes X-linked mental retardation for which there ... article to be published electronically on Tuesday, March 20, ... , Investigators F. Lucy Raymond (Cambridge Institute of Medical ... Tarpey (Wellcome Trust Sanger Institute, Hixton, UK) describe the ...
Cached Biology News:New sensor detects gaseous chemical weapon surrogates in 45 seconds 2Scientists uncover new target in cancer mutation puzzle 2Severe mental retardation gene mutation identified 2
... is a four-channel general purpose laboratory amplifier. It ... sources which may have a large common-mode level ... a high gain/low noise amplifier, an input coupling ... offset control. A control knob sets the amplifier ...
... Pro-OpioMelanoCortin (POMC) has long been ... prime precursor to a multiplicity of ... (-LPH), -endorphin, Alpha-Melanocyte Stimulating Hormone (a-MSH) ... very well-conserved molecule, being found in ...
...
...
Biology Products: